MedTrace Logo

To Evaluate the Effects of Omega 3 Fatty Acids in the Context of Cancer Prevention

NCT05427604 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-06-22

No results posted yet for this study

Summary

Previous studies have demonstrated, in an in vitro micro-tumour model (the spheroid) and in a mouse model, that long-chain omega-3 fatty acids, in particular docosahexaenoic acid (DHA), can inhibit tumour development.

Therefore, the aim of this study was to collect DHA-enriched human serum, following ingestion of a DHA-enriched oil, in order to assess its effect on tumour development in vitro. Blood enriched in fatty acids not containing DHA will be used as a control condition, obtained after ingestion of olive oil.

This study is an important step to determine the interest of DHA supplementation as a new approach to prevent tumour development, and/or as an adjuvant to cancer treatments.

Conditions

  • Healthy

Interventions

OTHER

Olive oil

ingestion of olive oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h

OTHER

Olive Oil

ingestion of olive oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)

OTHER

DHA oil

ingestion of DHA oil (3g) and blood measurement at baseline, after 1h, 2h, 3h, 4h, 5h, 6h

OTHER

DHA oil

ingestion of DHA oil (3g) and blood sampling at the fatty acids pic concentration (for in vitro study)

Sponsors & Collaborators

  • Université Catholique de Louvain

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-23
Primary Completion
2021-06-21
Completion
2021-06-21

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05427604 on ClinicalTrials.gov